Skip to main content
EJNMMI Research

Table 7 Lesion-based quantification parameters in T1 and T2

From: [68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study

Parameter

Prostatic lesions T1 [mean; CI]

Prostatic lesions T2 [mean; CI]

p

Lymphonodal lesions T1 [mean; CI]

Lymphonodal lesions T2 [mean; CI]

p

Bone lesions T1 [mean; CI]

Bone lesions T2 [mean; CI]

p

All lesions T1 [mean; CI]

All lesions T2 [mean; CI]

p

Score

2.33; 2.06–2.60

1.50; 1.07–1.93

0.001

2.00; 1.82–2.18

0.61; 0.35–0.86

 < 0.001

1.52; 1.26–1.78

0.48; 0.22–0.74

 < 0.001

1.94; 1.81–2.08

0.77;0.58–0.96

 < 0.001

SUVmax

29.13; 20.11–38.15

14.67; 9.02–20.32

0.002

20.65; 15.50–25.81

8.17; 2.79–13.55

 < 0.001

12.84; 8.27–17.41

3.48; 1.30–5.65

 < 0.001

20.44; 16.86–24.02

8.35; 5.24–11.46

 < 0.001

SUVmean

17.44; 11.99–22.89

8.63; 5.36–11.90

0.003

13.48; 10.09–16.86

5.10; 1.80–8.41

 < 0.001

8.36; 5.37–11.36

2.20; 0.80–3.61

 < 0.001

12.99; 10.72–15.26

5.11; 3.22–7.00

 < 0.001

PSMA-TV [ml]

11.82; 8.13–15.51

3.32; 1.52–5.13

 < 0.001

2.99; 1.39–4.60

0.23; 0.08–0.39

 < 0.001

1.88; 1.24–2.52

0.98; 0.23–1.75

0.013

4.64; 3.29–5.98

1.12; 0.63 -1.60

 < 0.001

TL-PSMA [ml]

253.16; 104.63–401.70

33.95; 9.68–58.22

 < 0.001

41.62; 19.70–63.53

4.62; 0–10.48

 < 0.001

21.03; 4.49–34.57

6.33; 0–13.65

 < 0.001

82.72; 45.49–119.94

11.53; 4.99–18.07

 < 0.001

Back to article page